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There are multiple mechanisms that protect the
intestine from an excessive inflammatory response
to intestinal microorganisms. We report here that all
four mammalian peptidoglycan recognition proteins
(PGRPs or Pglyrps) protect the host from colitis in-
duced by dextran sulfate sodium (DSS). Pglyrp1/,
Pglyrp2/, Pglyrp3/, and Pglyrp4/ mice are all
more sensitive than wild-type mice to DSS-induced
colitis due to a more inflammatory gut microflora,
higher production of interferon-g, higher expression
of interferon-inducible genes, and an increased
number of NK cells in the colon upon initial exposure
to DSS, which leads to severe hyperplasia of the
lamina propria, loss of epithelial cells, and ulceration
in the colon. Thus, during experimental colitis,
PGRPs protect the colon of wild-type mice from an
early inflammatory response and the loss of the
barrier function of intestinal epithelium by promoting
normal bacterial flora and by preventing damaging
production of interferon-g by NK cells in response
to injury.
INTRODUCTION
Mucosal surfaces, such as intestinal tract mucosa, rely both on
innate and adaptive immunity for protection against invasion
with commensals and pathogens. Much attention has been
focused on proinflammatory effects of pattern recognition
receptors, such as Toll-like receptors or Nod-like receptors,
which recognize various microbial components. In the intestinal
mucosa, a single layer of mucus-coated epithelial cells sepa-
rates billions of bacteria present in the colon from sterile tissues.
This barrier must not only prevent entrance of these bacteria
into the tissues, but it must also avoid mounting continuous
inflammatory response to the highly proinflammatory microbial
components present in the colon. Thus, the balance of the
immune responsiveness in the colon must be heavily tilted
toward unresponsiveness (or inhibition of inflammation). How-
ever, the mechanisms of maintaining this unresponsiveness
are not fully understood.Cell HoIn this study, we tested the role of peptidoglycan recognition
proteins (PGRPs or Pglyrps) in intestinal immunity. PGRPs are
innate immunity proteins that are conserved from insects to
mammals, recognize bacterial peptidoglycan, and function in
antibacterial immunity. Mammals have four PGRPs, Pglyrp1,
Pglyrp2, Pglyrp3, and Pglyrp4 (that were initially named
PGRP-S, PGRP-L, PGRP-Ia, and PGRP-Ib, respectively) (Kang
et al., 1998; Liu et al., 2001). Three PGRPs, Pglyrp1, Pglyrp3,
and Pglyrp4, are directly bactericidal (Lu et al., 2006; Tydell
et al., 2006; Wang et al., 2007), whereas Pglyrp2 is an N-acetyl-
muramoyl-L-alanine amidase that hydrolyzes peptidoglycan
(Gelius et al., 2003; Wang et al., 2003). Pglyrp1 is highly ex-
pressed in PMN’s granules and is also expressed in other cells,
e.g., intestinal M cells (Liu et al., 2000, 2001; Dziarski et al., 2003;
Lo et al., 2003). Pglyrp3 and Pglyrp4 are expressed in the skin,
salivary glands, throat, tongue, esophagus, stomach, intestine,
and eyes (Mathur et al., 2004; Lu et al., 2006). Pglyrp2 is consti-
tutively expressed in the liver and secreted into blood, and its
expression is induced in other cells, such as epithelial cells,
including intestinal epithelium (Gelius et al., 2003; Wang et al.,
2003; Lo et al., 2003; Xu et al., 2004; Wang et al., 2005; Zhang
et al., 2005; Li et al., 2006). Mammalian PGRPs could influence
host-parasite interactions through their antibacterial or peptido-
glycan-hydrolytic properties because normal bacterial flora is
crucial for maintaining proper mucosal homeostatic balance.
However, PGRPs also have immunomodulatory properties that
are independent of their hydrolytic and antibacterial activities
(Saha et al., 2009).
Based on these antibacterial and immunomodulatory proper-
ties of PGRPs and their expression in the intestine, we hypothe-
sized that mammalian PGRPs may play a role in the intestinal
inflammation. One of the most frequent inflammatory diseases
of unknown etiology in the intestinal tract is the inflammatory
bowel disease (IBD). IBD affects one in 500 individuals and is
characterized by chronic relapsing inflammation of the gastroin-
testinal tract likely due to dysregulated immune response to
intestinal bacteria. It includes Crohn’s disease and ulcerative
colitis. Crohn’s disease may affect the entire length of intestinal
tract and usually includes chronic granulomatous inflammation,
whereas ulcerative colitis affects primarily colon and lacks gran-
ulomatous inflammation (Podolsky, 2002; Sartor, 2003; Korzenik
and Podolsky, 2006; Hanauer, 2006; Lakatos et al., 2006).
To test whether PGRPs play a role in IBD, we selected a
dextran sulfate sodium (DSS)-induced colitis model. DSS-
induced colitis is an established experimental mouse model ofst & Microbe 8, 147–162, August 19, 2010 ª2010 Elsevier Inc. 147
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PGRPs Protect Mice from DSS-Induced Colitisacute colitis often used to study the role of innate immunity in IBD
and especially ulcerative colitis. Oral administration of DSS in
drinking water damages intestinal epithelium and induces
inflammation and ulcerative colitis, most likely in response to
enteric bacteria. The requirement for intestinal bacteria is evi-
denced by a drastic reduction of the intestinal inflammatory
response in this model by oral administration of antibiotics (Elson
et al., 1995; Rath et al., 2001; Rakoff-Nahoum et al., 2004;
Maeda et al., 2005).
We demonstrate that all four PGRPs protect mice from colitis
because Pglyrp1/, Pglyrp2/, Pglyrp3/, and Pglyrp4/
mice are all more sensitive than wild-type (WT) mice to DSS-in-
duced colitis. We show that PGRPs protect mice from colitis
by promoting normal intestinal flora that is less inflammatory
than flora of PGRP-deficient mice and by limiting production of
interferon-g (IFN-g) by NK cells in the colon upon initial exposure
to DSS. This allows WT mice to limit induction of IFN-inducible
genes, early inflammatory response, and damage to the colon.
RESULTS
PGRP-Deficient Mice Have Higher Susceptibility
to DSS-Induced Colitis
Oral administration of 3% DSS in drinking water to WT BALB/c
mice induced moderate colitis, manifested first by diarrhea and
then some blood in the stools, 15% weight loss, and 27%
mortality when DSS was continued for 20 days (Figure 1). By
contrast, Pglyrp1/, Pglyrp2/, Pglyrp3/, and Pglyrp4/
mice showed significantly higher sensitivity to DSS-induced
colitis than WT mice, manifested by extremely severe intestinal
bleeding, accelerated and more severe weight loss (28%–
34%), and accelerated and higher mortality (60%–95%) (Fig-
ure 1). Pglyrp2/ and Pglyrp3/mice were the most sensitive,
Pglyrp1/ mice had intermediate sensitivity, and Pglyrp4/
mice were the least sensitive. These results are consistent with
lower expression of Pglyrp4 than other PGRPs in most tissues,
including colon (Liu et al., 2001; Mathur et al., 2004; Lu et al.,
2006). PGRP-deficient mice were also similarly more sensitive
than WT mice to colitis induced by 5% DSS, which induced
more rapid andmore severe colitis in all mice (Figure S1 available
online).
To determine the pathologic basis of higher sensitivity of
PGRP-deficient mice to colitis, we compared the histology of
intestinal tract in WT and PGRP-deficient mice treated with
DSS. The most prominent changes were found in the colon,
with the most severe pathology in the distal colon. In both
proximal and distal colon, PGRP-deficient mice had extensive
hyperplasia of the lamina propria, thickened submucosa, loss
of morphology and crypt architecture, loss of epithelial layer,
decrease in goblet cells, and severe ulceration. By contrast,Figure 1. PGRP-Deficient Mice Are More Susceptible to DSS-Induced
(A) Gross rectal bleeding in Pglyrp3/ mice, but not in WT mice, after treatment
(B–D) (B) Survival, (C) body weight, and (D) stool and rectal bleeding scores of WT
treatment with 3% DSS in drinking water. n = 11–20 mice/group; significance o
*p < 0.05; **p < 0.001. In addition, Pglyrp2/ and Pglyrp3/ mice had signi
and Pglyrp3/ mice was significantly lower than Pglyrp4/ mice (p < 0.05)
Pglyrp3/ mice was significantly lower than Pglyrp4/ mice (p < 0.05) on days
Pglyrp3/ mice were significantly higher than Pglyrp4/ mice (p < 0.05) on day
Cell HoWTmice after the same length of DSS intake did not show these
changes (Figures 2 and S2). Within 4 days of administration of
5% DSS, hyperplasia of the lamina propria was visible in all
PGRP-deficient mice. However, the extent of hyperplasia was
different in different strains; it was extensive in Pglyrp2/ and
Pglyrp3/ mice, moderate in Pglyrp1/ mice, and mild in
Pglyrp4/ and WT mice. There was loss of epithelial cells in
small sections in Pglyrp2/ and Pglyrp3/ mice. By day 7,
there was extensive loss of epithelial layer, few remaining goblet
cells, and ulceration in all PGRP-deficient mice, with the most
severe changes in Pglyrp2/ and Pglyrp3/mice. Frank blood
was also present in the lumen in distal colon in all PGRP-deficient
mice. Similar but milder morphological changes were also seen
in the cecum in DSS-treated PGRP-deficient mice, whereas few
changes were seen in the small intestine (data not shown).
The progressive complete loss of colonic epithelium in PGRP-
deficient mice was the most likely cause of their mortality, as it
resulted in dehydration, because one of the important functions
of colonic epithelium is reabsorption of water. The death was not
due to the blood loss because there was no significant decrease
in hematocrit of DSS-treated mice (the loss of blood was likely
offset by dehydration) (data not shown). The death was also
not due to sepsis because bacterial cultures from the peritoneal
cavity and internal organs (liver, spleen, kidneys, and lungs)
revealed only low numbers of bacteria (on average, < 102–104/
organ) (data not shown), which are not sufficient to cause septic
shock and mortality. By comparison, in experimental infection
models, including cecal-ligation-and-puncture infection model
with endogenous intestinal bacteria, the numbers of bacteria
reach > 109/organ before mice die from sepsis (data not shown).
In PGRP-deficient mice, inflammatory cells (mainly PMNs and
lymphocytes) were seen scattered throughout the intestinal wall
and oftenmigrating through the intestinal wall, and in later stages
(day 7), pus was present in the lumen of the colon (Figures 2 and
S2). However, overall, the numbers of inflammatory cells were
not very high in light of full exposure of subepithelial layers to
the bacteria-laden contents of colonic lumen. Thus, the main
pathologic finding in PGRP-deficient mice was the loss of normal
colon morphology and architecture due to hyperplasia of the
lamina propria and loss of colonic epithelium with moderate
inflammation. These results demonstrate that all four PGRPs
play an important role in protecting mice against DSS-induced
tissue damage and colitis.
PGRPs Protect Mice from Induction of IFN-g
and Activation of IFN-Inducible Genes in the Colon
To determine the mechanism responsible for the higher sensi-
tivity of PGRP-deficient mice to DSS-induced colitis, we then
looked for the genes whose expression was differentially
induced in PGRP-deficient mice, compared to WT mice,Colitis Than WT Mice
with 3% DSS in drinking water.
and Pglyrp1/, Pglyrp2/, Pglyrp3/, and Pglyrp4/mice after continuous
f differences between PGRP-deficient and WT mice is indicated by asterisks;
ficantly more severe colitis than Pglyrp4/ mice: the survival of Pglyrp2/
on days 14–17 and 16–20, respectively; the weight of Pglyrp2/ mice and
15–18 and 11–14, respectively; and the stool scores of Pglyrp2/ mice and
s 12–14 and 9, 17, 18, respectively (see also Figure S1 and Table S1).
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Figure 2. DSS-Treated PGRP-Deficient Mice Have Colon Ulceration, Hyperplasia of the Lamina Propria, and Extensive Loss of Colonic
Epithelium
H&E stained cross-sections of the distal colon (and proximal colon in Figure S2) show normal histology in all untreated mice. Epithelial cells (E), lamina
propria (LP), goblet cells (G), muscularis mucosa (MM), submucosa (SM), and muscularis externa (ME) are indicated. By day 4 of DSS treatment, PGRP-deficient
mice showed hyperplasia of the lamina propria (*) and early stages in the loss of crypt architecture. By day 7, these changes were more pronounced and were
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PGRPs Protect Mice from DSS-Induced Colitisfollowing exposure to DSS. We first compared induction of
expression of 84 proinflammatory genes in WT and Pglyrp3/
mice 1, 2, 3, or 4 days after treatment with 4% or 5% DSS, using
qRT-PCR. We looked for the earliest and biggest difference in
induction of gene expression between Pglyrp3/ and WT
mice to identify the initial events that make PGRP-deficient
mice more susceptible to colitis. Treatment with both 4% and
5% DSS induced higher expression of proinflammatory genes
in Pglyrp3/ than WT mice. The biggest and the earliest differ-
ence was seen on day 2 of 5% DSS treatment: expression of
10 out of 84 proinflammatory genes was induced at least two
times higher in Pglyrp3/ mice than in WT mice. In particular,
chemokines CXCL-9, CXCL-10, CXCL-11, and CCL-8 and
IFN-g were induced 5 to 16 times higher in Pglyrp3/ than in
WT mice (highlighted in Table S1).
To perform unbiased analysis of gene expression in WT and
PGRP-deficient mice, we then used whole-genome expression
arrays to compare gene expression in WT mice and Pglyrp1/,
Pglyrp2/, Pglyrp3/, and Pglyrp4/ mice that were
untreated or treated for 2 days with 5% DSS. Out of 28,853
genes analyzed, 20,751 were expressed, and 1,883–2,728
genes were expressed significantly higher in PGRP-deficient
than in WT mice following DSS treatment, whereas 2,191–
3,751 genes were expressed significantly lower. The expression
of 32–115 genes was increased more than 2 times higher in
PGRP-deficient than in WT mice, whereas the expression of
only 6 to 14 genes was decreased more than 2 times in PGRP-
deficient than in WT mice (Table S2 and NCBI GEO accession
numberGSE18859). These results indicate an overall higher level
of gene activation following DSS treatment in PGRP-deficient
than in WT mice.
We then further analyzed the array data to identify the common
genes that were induced higher in PGRP-deficient mice than in
WT mice by DSS treatment. We first compared the induction of
gene expression in the colon after 2 days of treatment with 5%
DSS in each knockout strain individually (Pglyrp1/, Pglyrp2/,
Pglyrp3/, and Pglyrp4/) to the induction of gene expression
in WT mice using the whole-genome arrays. For each data set
comparing Pglyrp/ mice to WT mice, we arranged all of the
genes on the array in descending order from the highest to the
lowest ratio of gene induction in Pglyrp/ mice versus WT
mice (these data sets have been deposited in NCBI GEO, acces-
sion number GSE18859). In this study, we focused on the
common mechanism of increased sensitivity to colitis in all four
PGRP-deficient mice. Therefore, we then merged the above
four whole-genome array data sets for Pglyrp1/, Pglyrp2/,
Pglyrp3/, and Pglyrp4/ mice (each compared to WT mice)
to identify the top common genes differentially expressed in all
PGRP-deficient versus WT mice.
The majority of genes that were induced higher in all four
PGRP-deficient strains of mice than in WT mice after DSS treat-
ment were IFN-inducible genes (90% of the top 50 genes and
83% of the top 75 genes). The expression of these genes was
increased in the colon in PGRP-deficient mice by DSS, whereasaccompanied by a decrease in the number of goblet cells, extensive loss of epithe
lumen (Bl) was present in distal colon in DSS-treated PGRP-deficient mice. Repr
magnification. Scale bar, 50 mm (see also Table S2).
Cell Hoit was reduced or unchanged in WT mice, as demonstrated by
the whole-genome array (Table S3). We confirmed that induction
of the top 75 IFN-inducible genes is higher in all PGRP-deficient
than in WT mice, using qRT-PCR (Figure 3 and Table S3).
Becausemammals havemany IFN genes, we next determined
which IFNs were induced by DSS treatment in the colon of
PGRP-deficient mice. After 2 days of treatment with 5% DSS,
WT mice did not increase the expression of any of the 16
IFN genes in the colon. By contrast, the same treatment in
PGRP-deficient mice significantly increased the expression of
IFN-g (Ifng) in the colon, but not any of the other 15 IFN genes
(Figure 4A). These results indicate that the genes most highly
and preferentially induced in all PGRP-deficient mice (Figure 3
and Table S3) are genes that are known to be IFN inducible (Bor-
den et al., 2007; Sadler and Williams, 2008) and are most likely
induced by IFN-g.
IFN-g Is Required for Full Manifestation of Colitis
in PGRP-Deficient Mice
To determine whether IFN-g is required for the development of
colitis in PGRP-deficient mice in vivo, we determined the sensi-
tivity to DSS-induced colitis of Pglyrp3/ mice in which IFN-g
activity was inhibited with neutralizing anti-IFN-g mAb. These
mice had significantly higher survival (Figure 4B, similar to the
survival of WT mice; Figure S1) and significantly lower weight
loss and stool scores (data not shown) than mice treated with
isotype control IgG following exposure to DSS. These results
demonstrate that IFN-g is required for full manifestation of
severe colitis in PGRP-deficient mice and show that induction
of IFN-g is not merely a consequence of mucosal damage.
PGRPs Protect Mice from DSS-Induced Increase
in NK Cells but Do Not Influence Th1, Th2,
and Th17 Responses in the Colon
Twomain cells that produce IFN-g are Th1 cells and NK cells. To
find the source of IFN-g, we first tested which cells were prefer-
entially increased in the colons of DSS-treated PGRP-deficient
mice, compared to WT mice. We measured the amounts of
RNA for marker genes characteristic of various immune and
inflammatory cell types in the colon. After 2 days of 5% DSS
treatment, NK cells and PMNs were significantly increased in
the colons of PGRP-deficient mice, but not WT mice (Figure 5A).
At that time, B cells, T cells (total T cells and CD4+ and CD8+
T cells), monocytes, and macrophages were not significantly
increased in the colons of any DSS-treated strains. These results
suggest that NK cells may be the source of INF-g in PGRP-
deficient mice and are consistent with higher induction of
chemokines in PGRP-deficient mice and the overall moderate
inflammatory response in the colon.
To further investigate the source of IFN-g, we measured the
expression of an extended panel of cytokines, chemokines,
and other marker genes characteristic of Th1, Th2, Th17, and
NK cells to determine which of these genes were differentially
induced in the colons of PGRP-deficient mice, compared tolial cells (/), ulceration (U), and infiltration with PMNs (PMN). Frank blood in the
esentative results from 6–12 mice/group are shown. All panels are at the same
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Figure 3. Higher expression of IFN-Inducible Genes in the Colon in PGRP-Deficient Than in WT Mice following DSS Treatment
(A) Top 75 genes expressed higher in the colon of PGRP-deficient than WT mice after 2 days of oral treatment with 5% DSS were identified by whole-genome
expression array as mostly IFN-inducible genes. Their expression is shown here measured by qRT-PCR. The results are the ratio of the amount of mRNA in
DSS-treated to untreated mice. The gene symbols are (IFN-inducible genes are underlined): A1–12: Iigp1, Tgtp, Indo1, Ifit2, H28, Ifi44, Igtp, Upp1, Cxcl10,
Gbp1, Cxcl9, Mpa2l; B1–12: Ifi47, Gbp2, Usp18, Slfn4, Gbp5, Gbp4, Zbp1, Trim30, Oas3, Irgm1, Apol9b, Gbp6; C1–12: Oas2, Ifit3, Tap1, Oasl2, Stat1,
Herc5, Ifit1, Tnfsf10, Mx2, Ccl8, Ly6a, Psmb8; D1–12: Rsad2, Phf11, Cmpk2, Cxcl11, Ms4a1, Nlrc5, Ddx60, Ly6e, Nos2, Isg15, Mx1, Slfn2; E1–12: Psmb9,
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PGRPs Protect Mice from DSS-Induced ColitisWTmice, following exposure to DSS. We included Th1, Th2, and
Th17 marker genes because Th1 cells are the major source of
IFN-g, and enhanced Th1 and Th17 responses are often associ-
ated with IBD and with several experimental models of colitis
(Watanabe et al., 2004, 2006; Yen et al., 2006).
In this extended Th1, Th2, Th17, and NK cell profile of
84 genes, the only genes preferentially induced by DSS in all
PGRP-deficient mice, compared to WT mice, were Ifng and
IFN-inducible genes Cxcl9, Cxcl10, Cxcl11, Ccl8, and Nos2
(Figure 3B and Table S4). Kinetic analysis of the expression of
IFN-g and four IFN-inducible chemokines revealed preferential
activation of all of these genes in Pglyrp3/ mice, but not in
WT mice on days 2, 3, and 4 of DSS treatment (Figure 3C). Our
results suggest that IFN-g originated from NK cells because
the induction of the above genes is a typical NK cell profile and
because there was an increase in the number of NK cells in
DSS-treated PGRP-deficient, but not WT mice (Figure 5A). It
was unlikely that IFN-g originated from Th1 cells because
expression of other Th1 marker genes (such as Il2, Tnf, Il18,
Il18bp, and Irf1) was not higher in PGRP-deficient than in WT
mice (Table S4). A similar pattern of higher expression of Ifng
and IFN-inducible genes Cxcl9, Cxcl10, Cxcl11, and Ccl8 was
also seen in colonic epithelial cells isolated from DSS-treated
Pglyrp1/, Pglyrp2/, Pglyrp3/, and Pglyrp4/ (but not
WT) mice (data not shown), indicating that IFN-g was produced
at or near the epithelial cell layer.
We also tested whether higher expression of these IFN-induc-
ible chemokines in PGRP-deficient than in WT mice was solely
due to the higher production of IFN in these mice or also due
to higher responsiveness of cells from PGRP-deficient mice to
IFN. We used cultured primary colonic fibroblasts, which are
one of the target cells for IFN and are known to be high producers
of proinflammatory chemokines. Primary colonic fibroblasts
from PGRP-deficient mice produced the same amounts of
Cxcl9, Cxcl10, Cxcl11, and Ccl8 mRNA as fibroblasts from WT
mice following stimulation with IFN-g (Figure S3). These results
confirm that the difference in the responses of PGRP-deficient
and WT mice is due to the higher IFN-g production and not
due to increased responsiveness to IFN-g.
The genes characteristic of Th17 (Il17a, Il17f, Il21, Il22, Il23a,
Cxcl1, Cxcl2, Cxcl5, Tgfb1, Sele, and Vcam1) or Th2 (Il3, Il4, Il5,
Il9, Il10, and Il13) responses were not preferentially induced in
the colons of DSS-treated PGRP-deficient mice compared to
WT mice (Table S4). Our results, therefore, indicate that there is
preferential increase in NK cells and production of IFN-g (likely
byNKcells)andnopreferential shift toTh1,Th17,orTh2 responses
in the colon ofDSS-treated PGRP-deficientmice compared toWT
mice. Thus, PGRPs protect the colon from excessive damage by
limiting IFN-g production and infiltration with NK cells.Stat2, Reg3b, Gzmb, Insig1, Klhl6, Rtp4, Ube2l6, Xdh, Cd274, Cd72, Rnf213; F1
Ifi27, Cxcr5; G1–3: Mlkl, Lgals9, Cd74. Gene descriptions and detailed results ar
(B and C) IFN-g and IFN-inducible chemokines are preferentially induced by D
inflammatory genes expressed higher in the colon of PGRP-deficient than WT m
chemokines, and other marker genes for various immune cell typeswere identified
CCL-8, and iNOS-2), which are characteristic of an NK cell profile. The results ar
results for all 84 genes are shown in Table S4. (C) Kinetics of induction of IFN-g
WT mice; means of three assays on five mice/group ± SEM.
See also Figure S3.
Cell HoNK Cells Are Required for Full Manifestation of Colitis
in PGRP-Deficient Mice
To determine the role of NK cells in the development of colitis
in PGRP-deficient mice in vivo, we compared the sensitivity
of NK-cell-depleted and not depleted Pglyrp3/ mice to
DSS-induced colitis. Pglyrp3/ mice depleted of NK cells with
anti-AsiloGM1 Abs had significantly higher survival (Figure 5B)
and significantly lower stool scores (data not shown) than mice
injected with control IgG following treatment with DSS. These
results demonstrate that NK cells are required for full manifesta-
tion of severe colitis in PGRP-deficient mice and show that
recruitment of NK cells is not merely a consequence of mucosal
damage.
PGRPs Are Differentially Expressed in Various Parts
of Oral Cavity and Gastrointestinal Tract
To gain further insight how PGRPs cause greater sensitivity to
colitis, we compared expression of all PGRPs in various sites
in the oral cavity and gastrointestinal tract. All PGRPs were
expressed in most sites in the oral cavity and gastrointestinal
tract, but their level of expression varied. Pglyrp1 was highly
expressed in most parts of the gastrointestinal tract, and its
expression was the highest in the oral cavity, ileum, and cecum
(Figure S4). Pglyrp2 was highly expressed in the esophagus
and throughout the small and large intestine. Pglyrp3 was highly
expressed in the esophagus, tongue, and throat, whereas
Pglyrp4 was primarily expressed in the esophagus, salivary
glands, tongue, throat, and lactating mammary glands, but the
overall expression of Pglyrp4 in these tissues was much lower
than of other PGRPs. Pglyrp3 and Pglyrp4 had very low expres-
sion in other parts of the gastrointestinal tract (Figure S4). These
results confirm and extend previous results in humans (Liu et al.,
2001; Lu et al., 2006) and mice (Mathur et al., 2004). One possi-
bility of how low expression of Pglyrp3 and Pglyrp4 in the colon
could influence colitis could be through upregulation of Pglyrp3
and Pglyrp4 expression during early stages of colitis. Indeed,
expression of all PGRPs in the colon was significantly increased
by the treatment with DSS, and expression of Pglyrp2, Pglyrp3,
and Pglyrp4 in cultured primary colonic fibroblasts was also
significantly increased by the treatment with bacteria or cyto-
kines (Figure S5).
PGRPs Change Bacterial Flora in the Intestine
Because PGRPs have antibacterial or peptidoglycan-lytic
activities, one possibility of how expression of PGRPs in the
intestinal tract could affect the sensitivity of the host to colitis
could be through influencing the composition of the gastrointes-
tinal bacterial flora. This mechanism could be especially appli-
cable to Pglyrp3 and Pglyrp4, which are highly expressed in–12: Dhx58, Ly6c1, Fcgr4, Trim15, Art2a, Cd19, Batf2, Parp9, Pbef1, Parp14,
e shown in Table S3.
SS treatment in the colon in PGRP-deficient, but not in WT, mice. (B) Top 6
ice after 2 days of oral treatment with 5% DSS out of a panel of 84 cytokines,
by qRT-PCR as IFN-g- and IFN-inducible genes (CXCL-9, CXCL-10, CXCL-11,
e the ratio of the amount of mRNA in DSS-treated to untreated mice. Detailed
- and IFN-inducible chemokines in the colon in DSS-treated Pglyrp3/ and
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Figure 4. IFN-g Is Preferentially Induced by DSS Treatment in the
Colon in PGRP-Deficient, but Not in WT, Mice, and IFN-g Is Required
for Full Manifestation of Colitis in PGRP-Deficient Mice
(A) Expression of 16 IFN genes was measured by qRT-PCR in the colons of
PGRP-deficient and WT mice after 2 days of oral treatment with 5% DSS.
The results are the ratio of the amount of mRNA in DSS-treated to untreated
mice; means of three assays on five mice/group ± SEM; significance of
differences between PGRP-deficient and WT mice is indicated by an asterisk.
*p < 0.01.
(B) Higher survival of Pglyrp3/ mice treated with neutralizing anti-IFN-g
mAbs than IgG-injected control mice following treatment with 5% DSS in
drinking water for 11 days; six mice/group. *p = 0.01.
See also Figure S4 and Table S4.
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even lactating mammary glands. To test this hypothesis, we
compared the composition of bacterial flora in the stools of WT
and PGRP-deficient mice by measuring the amounts of DNA
for all Eubacteria and for eight major groups of mouse intestinal
bacteria using previously validated qPCR methods (Barman
et al., 2008; Salzman et al., 2010). PGRP-deficient mice had
significant changes in the composition of their bacterial flora in
their stools. The amounts of bacteria from the following bacterial
groupswere significantly reduced in the following knockout mice
compared to WT mice: Lactobacillus/Lactococcus group in
Pglyrp2/, Pglyrp3/, and Pglyrp4/ mice; Segmented
Filamentous bacteria group in Pglyrp1/, Pglyrp2/, and
Pglyrp4/ mice; Clostridium perfringens group in Pglyrp2/
and Pglyrp3/ mice; and Enterobacteriaceae and Eubacterium
rectale/Clostridium coccoides groups in Pglyrp3/ mice (Fig-
ure 6A). Mouse Intestinal Bacteroides group was also sig-
nificantly decreased in Pglyrp2/ mice and increased in
Pglyrp4/ mice. These results indicate that all PGRPs are
important for maintaining the balance of normal flora in the gut
and that deficiencies in individual PGRPs can cause significant,
but not identical, changes in gut normal flora.
Intestinal Flora from PGRP-Deficient Mice Increases
Sensitivity to Colitis
We next considered whether the above changes in normal gut
flora in PGRP-deficient mice have any functional consequences.
First, we tested whether it differentially induces cytokine produc-
tion by intestinal cells. Indeed, stools from PGRP-deficient mice
have significantly higher capacity to induce cytokine (IL-6) and
chemokine (CXCL-1) production in cultured primary mouse
colonic fibroblasts (Figure 6B) and peritoneal macrophages
(Figure S6) than stools from WT mice. Of note, Pglyrp3/ and
Pglyrp2/ mice, which were the most sensitive to colitis, had
the most changes in their gut flora, and their stools had the high-
est cell-activating capacity, whereas Pglyrp1/ and Pglyrp4/
mice, which were less sensitive to colitis, had fewer changes in
the gut flora, and their stools had lower cell-activating capacity.
Second, we tested whether the imbalance in normal flora
caused by the lack of individual PGRPs and a shift to microflora
with higher capacity to stimulate proinflammatory cytokines and
chemokines in host intestinal cells predisposed mice to the
higher sensitivity to colitis. We treated germ-free mice with daily
gavages of stools from WT or PGRP-deficient mice and oral 4%
DSS in drinking water. Germ-free mice receiving stools fromr Inc.
Figure 5. DSS Treatment Results in Early Increase in NK Cells
and PMNs in the Colon in PGRP-Deficient, but Not in WT, Mice,
and NK Cells Are Required for Full Manifestation of Colitis in
PGRP-Deficient Mice
(A) The amounts of mRNA for the indicated marker genes characteristic of B
cells, T cells, NK cells, macrophages (MF), and PMNs were measured by
qRT-PCR in the colons of PGRP-deficient and WT mice after 2 days of oral
treatment with 5% DSS. The results are the ratio of the amount of mRNA in
DSS-treated to untreated mice; means of three assays on five mice/group ±
SEM; significance of differences between PGRP-deficient and WT mice is
indicated by an asterisk. *p < 0.01.
(B) Higher survival of Pglyrp3/mice depleted of NK cells with anti-AsiloGM1
Ab than IgG-injected control mice following treatment with 5%DSS in drinking
water for 11 days; six mice/group, *p = 0.01.
See also Figure S5.
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Cell HoPglyrp2/mice or Pglyrp3/mice were more sensitive to DSS
colitis than mice receiving stools from WT mice, as manifested
by significantly higher mortality, significantly higher weight
loss, and significantly higher colitis scores (Figures 7A–7C
and S7). Therefore, a shift in intestinal flora to more damaging
proinflammatory microbiota is an important cause of increased
sensitivity to colitis in PGRP-deficient mice. Thus, PGRPs
promote normal intestinal flora that protects WT mice from
severe colitis.
PGRPs Do Not Induce Signal Transduction Inhibitors
in the Colon
We also tested a possibility that the protective effect of PGRPs
could be exerted through induction of inhibitors of inflammatory
pathways. If this was the mechanism of PGRP action, deleting
PGRPs would result in lower production of inhibitors, which
would cause higher cytokine responses and increased inflam-
mation. Because IFN can be induced through activation of
Toll-like receptors, we tested whether several inhibitors known
to regulate TLR signaling (Rothlin et al., 2007; Watanabe et al.,
2008) are differentially induced in DSS-treated PGRP-deficient
and WT mice. However, none of the 12 known inhibitors of
inflammatory pathways that we have tested by qRT-PCR (Atf3,
Bcl3, Il18bp, Inpp5d, Irak3, Irf1, Irf4, Irf7, Rnf216, Socs1,
Socs3, and Tollip) was expressed lower in PGRP-deficient than
in WT mice (Table S5). The expression of these inhibitors was
also not decreased in PGRP-deficient mice in the whole-genome
arrays (data not shown; see NCBI GEO accession number
GSE18859). Expression of other relevant inhibitors, such as
TAM receptors (Tyro3, Axl, and Mertk) (Rothlin et al., 2007), Irf2
(IFN regulatory factor 2), and pyrimidinergic and purinergic
receptors (P2ry4, P2ry6, and P2ry14), that modulate IFN
responses (Hida et al., 2000; Shin et al., 2008) was also not
changed after treatment with DSS in PGRP-deficient mice com-
pared toWTmice, as determined by whole-genome arrays (data
not shown; see NCBI GEO accession number GSE18859). There
were no known IFN inhibitors in the 100 most downregulated
genes in PGRP-deficient mice compared to WT mice following
DSS treatment determined by the whole-genome arrays (data
not shown; see NCBI GEO accession number GSE18859).
Some inhibitors, e.g., Socs1 (suppressor of cytokine signaling
1) and Zbp1 (Z-DNA-binding protein 1, which is an IFN-regula-
tory factor), were increased in DSS-treated PGRP-deficientst & Microbe 8, 147–162, August 19, 2010 ª2010 Elsevier Inc. 155
Cell Host & Microbe
PGRPs Protect Mice from DSS-Induced Colitis
156 Cell Host & Microbe 8, 147–162, August 19, 2010 ª2010 Elsevier Inc.
Cell Host & Microbe
PGRPs Protect Mice from DSS-Induced Colitismice compared to WT mice (Tables S3 and S5), which indicates
activation of inhibitory feedback mechanisms by higher induc-
tion of cytokines in PGRP-deficient compared to WT mice.
These results indicate that PGRPs do not exert their anti-inflam-
matory effect through induction of higher expression of the
above inhibitors.
DISCUSSION
There are multiple mechanisms of maintaining tolerance in the
gut that protect the intestine from excessive inflammatory
response to intestinal microorganisms and damage to the intes-
tinal wall. We report here a mechanism in which all four mamma-
lian PGRPs protect the host from DSS-induced colitis. We show
that Pglyrp1/, Pglyrp2/, Pglyrp3/, and Pglyrp4/ mice
are all more sensitive than WT mice to DSS-induced colitis.
The key events controlled by PGRPs are maintaining less inflam-
matory normal intestinal flora, resistance to production of IFN-g,
and resistance to infiltration with NK cells in the colon upon initial
exposure to DSS. This allowsWTmice to avoid induction of early
inflammatory response and damage in the colon. In contrast to
WT mice, all PGRP-deficient mice have intestinal flora with
higher proinflammatory activity and have high induction of
IFN-g in the colon followed by robust activation of IFN-inducible
genes, including CXCL-9, CXCL-10, and CXCL-11, which attract
more IFN-g-producing NK cells. This cycle then leads to the early
changes in colon morphology, loss of epithelial lining in the
colon, inflammation, and increased mortality (Figure 7D).
Microbial flora in the gut has a great influence on the develop-
ment of the immune system, and changes in the intestinal flora
often determine the sensitivity to inflammatory diseases and
the outcomes of host-pathogen interactions (Sansonetti and
Medzhitov, 2009). Our results demonstrate that PGRPs (which
have bactericidal or bacteriolytic activities) significantly influence
normal flora in the gut. Deficiencies in individual PGRPs result in
significant changes in the normal bacterial flora in the colon to
the extent that the stools from PGRP-deficient mice have higher
immunostimulatory activity than the stools from WT mice and,
when transferred to germ-free mice, induce higher sensitivity to
colitis than stools from WT mice. Such a change could be, for
example, due to a decrease in the number of Lactobacilli, which
are usually considered as beneficial probiotics, although detailed
analysis of which bacteria are responsible for this effect will
require further study. Nevertheless, our results offer one possible
explanation of howadeficiency in a singlePGRP increases sensi-
tivity to colitis and also of how relatively high expression of
PGRPs in theoral cavity, salivary glands, and the upper segments
of the gastrointestinal tract influence the outcome of colitis
through induction of changes in the intestinal flora.
Changes in intestinal flora have been also observed in other
models of IBD. For example, NOD2 is one of the strongestFigure 6. PGRP-Deficient Mice Have Changes in Intestinal Bacterial Fl
(A) Changes in the composition of bacterial flora in the stools of WT and PGRP
Intestinal (MI) Bacteroides, Bacteroides sp., Eubacterium rectale/Clostridium co
tous bacteria (SFB), Enterobacteriaceae, and Clostridium perfringens, measured
(B) Higher induction of IL-6 andCXCL-1 production in cultures of primary colonicW
of five experiments ± SEM. *p% 0.05 versus WT (paired t test).
See also Figure S6.
Cell Hogenetic risk factors for Crohn’s disease, and NOD2-deficient
mice have changes in intestinal flora that result in a diminished
ability to prevent intestinal colonization with pathogenic bacteria
and to effectively kill these bacteria in the intestine (Petnicki-
Ocwieja et al., 2009). Moreover, bacterial flora in the gut has
also systemic influence on inflammatory diseases not only in
the intestine, but also in other organs, such as joints and lungs
(Maslowski et al., 2009). Thus, effects of PGRPs on the intestinal
flora could have systemic consequences in other inflammatory
diseases.
The involvement of NK cells in colitis is consistent with the
current notion of NK cells being ‘‘conductors of inflammatory
responses’’ (Di Santo, 2008). The proposed involvement of
IFN-g-producing NK cells rather than Th1 cells in DSS-induced
colitis is also consistent with the notion that this form of colitis
is due to direct damage of epithelial cells in the colon, that it
more closely resembles human ulcerative colitis, and that it is
based on innate (rather than T cell-mediated) response (Xavier
and Podolsky, 2007; Zenewicz et al., 2008). Ulcerative colitis
and its DSS model contrast Crohn’s disease, which involves
granulomatous infiltrations of both small intestine and colon,
which is primarily Th1 dependent and for which IL-22-producing
NK cells are protective (Watanabe et al., 2004; Rakoff-Nahoum
et al., 2006; Zenewicz et al., 2008). Our results demonstrate
a protective role of PGRPs and a proinflammatory role of IFN-g
and IFN-g-producing NK cells in DSS-induced colitis and further
confirm a proinflammatory role of IFN-g and IFN-induced
chemokines in colitis.
IFN production can lead to colitis, as evidenced by sponta-
neous development of intestinal inflammation similar to ulcera-
tive colitis as a side effect in patients treated with IFN for viral
infections (Wenner and Piccoli, 1997; Mavrogiannis et al., 2001;
Sprenger et al., 2005). Moreover, NK cells from IBD patients
produce increased amounts of IFN-g (Liu et al., 2009). Our
results are consistent with the above reports and with other
findings of a pivotal role of IFN-g in DSS colitis through induction
of apoptosis and inhibition of proliferation of colonic epithelial
cells (Ito et al., 2006; Nava et al., 2010), as well as with previous
reports demonstrating the role of IFN and IFN-induced NK cell-
attracting chemokines CXCL-9, CXCL-10, and CXCL-11 and
their receptor CXCR3 in various models of colitis (Watanabe
et al., 2004, 2006; Rakoff-Nahoum et al., 2006; Louis et al.,
2008) and in patients with IBD (Parronchi et al., 1997; Singh
et al., 2007; Strober et al., 2007; Budarf et al., 2009). Their role
in the pathogenesis of IBD is also supported by the effectiveness
of anti-CXCL-10 antibodies or blocking CXCR3 in the treatment
of colitis (Singh et al., 2007).
Our results reveal an in vivo role of PGRPs as anti-inflamma-
tory proteins that prevent damaging production of IFN-g in
response to injury. PGRPs have an indirect effect on colitis
through modulation of intestinal flora, as discussed above.ora that Induce Higher Cytokine and Chemokine Production
-deficient mice in all Eubacteria and in the following bacterial groups: Mouse
ccoides, Clostridium leptum, Lactobacillus/Lactococcus, Segmented filamen-
by qPCR; means ± SEM of 12 mice per group. *p% 0.05 versus WT (t test).
Tmouse fibroblasts by stools fromPGRP-deficient than fromWTmice; means
st & Microbe 8, 147–162, August 19, 2010 ª2010 Elsevier Inc. 157
Figure 7. Intestinal Flora from PGRP-Deficient Mice Renders Germ-
Free Mice More Susceptible to DSS-Induced Colitis Than Intestinal
Flora from WT Mice
(A–C) (A) Survival, (B) body weight, and (C) stool and rectal bleeding scores of
WT germ-free mice continuously treated for 18 days with 4% DSS in drinking
water and gavaged daily with stool homogenates from conventionally raised
WT, Pglyrp2/, or Pglyrp3/mice. n = 10 mice/group (from two experiments
with five mice/group in each experiment). Significance of differences between
mice gavaged with stools from PGRP-deficient and WT mice is indicated by
asterisks. *p < 0.05; **p < 0.005. See also Figure S7.
(D) Sequence of events leading to more severe colitis in PGRP-deficient mice.
See also Table S5.
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previously shown in an arthritis model (Saha et al., 2009). All
PGRPs are expressed along the entire length of the gastrointes-
tinal tract, with the highest expression in the upper segments
(oral cavity, esophagus, and salivary glands), including intestinal
epithelial cells, and their expression is increased following
treatment with DSS or stimulation with bacteria or cytokines.
However, PGRPs are usually not expressed in immune cells,
such as lymphocytes, monocytes, and macrophages (Liu et al.,
2000, 2001; Wang et al., 2005; Lu et al., 2006; Li et al., 2006).
Thus, PGRPs are likely to exert their effects on local nonimmune
cells in the gut, such as epithelial cells and fibroblasts, which
are rich sources of chemokines, including NK cell-attracting
CXCL-9, CXCL-10, and CXCL-11 (Figure S3).
We recently observed an opposite effect of Pglyrp2 in a model
of peptidoglycan-induced arthritis, i.e., Pglyrp2 has a proinflam-
matory effect and is required for the induction of arthritis by
peptidoglycan in BALB/c mice (Saha et al., 2009). By contrast,
other PGRPs have no proinflammatory effect in this arthritis
model, and Pglyrp1 is anti-inflammatory, similar to its effect in
the colon observed in the current study. Such anti-inflammatory
and proinflammatory effects in various models of inflammation
are not unique to PGRPs, as some cytokines also have dual
pro- and anti-inflammatory effects depending on the local
milieu and the types of effector and target cells involved in
the inflammatory process. For example, IL-22 targets nonim-
mune cells, such as epithelial cells, endothelial cells, keratino-
cytes, and fibroblasts, and has a proinflammatory effect in the
skin (Zheng et al., 2007; Ma et al., 2008) and anti-inflammatory
effect in the gastrointestinal tract (Sugimoto et al., 2008; Zene-
wicz et al., 2008). Similarly, local cells that produce cytokines
and are targets for cytokines, e.g., fibroblasts, are heteroge-
nous in various organs and tissues and show different respon-
siveness to various stimulatory signals (Koumas et al., 2002;
Smith, 2005).
Mammalian Pglyrp2 is an N-acetylmuramoyl-L-alanine ami-
dase that hydrolyzes bacterial cell wall peptidoglycan (Gelius
et al., 2003; Wang et al., 2003). However, its amidase activity
is not required for its pro-inflammatory effect in the arthritis
model (Saha et al., 2009). The amidase activity is also likely
not required for the anti-inflammatory effect of PGRPs reported
here, because all four PGRPs have this anti-inflammatory effect,
and only one of these PGRPs (Pglyrp2) has amidase activity
(Wang et al., 2003). These results are consistent with the
emerging view that many proteins possess multiple functions
in vivo.r Inc.
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mined both by genetic predisposition and environmental factors.
Initial genetic analysis identified nine genetic loci that predispose
patients to IBD (Lakatos et al., 2006). The first gene identified in
one of these loci that predisposes patients to the Crohn’s
disease form of IBD is a mutated NOD2 (Hugot et al., 2001;
Ogura et al., 2001). More recent large-scale genome-wide
association screenings identified 34 loci, in which more than
20 genes have proven significant association with IBD, including
IL23R, ATG16L1, IL12B, and IL10 (Cho, 2008; Budarf et al.,
2009). These findings opened up a possibility of still many
more so far unidentified genes to be associated with IBD, espe-
cially that specific genes still have not been identified in all of
the above IBD susceptibility loci. Of interest to our results is
the susceptibility locus 19p13 (originally named IBD6 locus)
(Rioux et al., 2000; Lakatos et al., 2006), for which the suscepti-
bility gene still has not been identified (Budarf et al., 2009) and
which harbors human PGLYRP2 at position 19p13.12. Thus,
PGLYRP2 could be one of the human IBD susceptibility genes
in this locus. Although other human PGRPs do not map to any
of the above 34 IBD susceptibility loci, it is still possible that
mutations in these PGRPs could also predispose patients to
IBD because many more genes are associated with IBD than
initially suspected. Genotyping of IBD patients is underway to
test these possibilities.
The observation that mice deficient in single PGRP genes are
all more sensitive to colitis indicates that the functions of four
mammalian PGRPs are not identical and nonredundant and
suggests that the mechanisms through which individual PGRPs
protect mice from colitis are at least partially different. In this
report, we focused on the similarities among all four PGRPs
and we designed our analysis of gene expression to identify
common genes whose expression is similarly changed in colitis
in all four PGRP-deficient strains. The rationale for this approach
was to identify steps that are common in the pathogenesis of
colitis in all four PGRP-deficient strains because all PGRPs
recognize peptidoglycan and are antibacterial. We reveal that
the common steps in the pathogenesis of colitis in all PGRP-
deficient mice are changes in the intestinal microflora, induction
of NK cell-attracting chemokines, NK cell infiltration, IFN-g
production by NK cells, and activation of IFN-inducible genes,
followed by loss of colon morphology and epithelial layer
(Figure 7D). However, the colitis phenotype in all four PGRP-
deficient strains is not the same. The severity of colitis and
kinetics of its development, as well as some details of pathology,
are not the same in all four strains. Similarly, gene expression
profiles in whole-genome expression arrays showed both simi-
larities (on which we focused in this study) and differences (on
which we will focus in future studies). This is not surprising
because all four PGRPs were preserved in evolution in all
mammals, because each PGRP has a different expression
pattern, and because deficiencies in each PGRP cause noniden-
tical changes in gut flora. This possibility could thus explain non-
redundancy of PGRPs in increased sensitivity to colitis if
changes in the gut flora in each PGRP-deficient strain are suffi-
ciently similar to increase sensitivity to colitis, but not identical.
This would result in some similarities and some differences
between pathogenesis and manifestations of colitis in each
PGRP-deficient strain. Colitis is a complex disease with severalCell Hointeracting pathogenic mechanisms determined by many
genetic, microbial, and other environmental factors. Our results
offer a possible link between the previously observed antibacte-
rial activities of PGRPs and their immunomodulatory effects
in vivo.
EXPERIMENTAL PROCEDURES
Mice
We generated Pglyrp1/, Pglyrp2/, Pglyrp3/, and Pglyrp4/ mice by
deleting exons 1, 1–4, 2–5, or 3–4, respectively, followed by backcrossing to
BALB/c background, as described in the Supplemental Information and
Figure S8.
Colitis Model, Neutralization of IFN-g, and Depletion of NK Cells
To induce experimental colitis female 8- to 10-week-old mice were given 3%,
4%, or 5% DSS (dextran sulfate sodium, MP Biomedicals) in drinking water
(Elson et al., 1995). The development of colitis was evaluated as described
in the Supplemental Information, using: (1) severity of colitis based on stool
and rectal bleeding scores of 0–16; (2) weight loss; (3) mortality; and (4)
histological analysis. The significance of differences in colitis scores and
weight loss were determined using two-sample t test and mortality using
chi-square test. IFN-gwas neutralized inPglyrp3/mice by intravenous injec-
tions of anti-IFN-g mAb (rat clone XMG1.2, endotoxin-free from Southern
Biotech, 100 mg on day 0 and 50 mg on days 2, 4, 6, and 8 of 5% DSS treat-
ment). Control mice were similarly treated with isotype control rat IgG1k
anti-KLH mAb (rat clone KLH/G1-2-2, endotoxin-free from Southern Biotech).
NK cells were depleted from Pglyrp3/mice by intravenous injections of 40 ml
anti-Asilo-GM1Abs (WakoChemicals) (Kasai et al., 1981) on days 0, 3, and 7 of
5% DSS treatment, which resulted in sustained > 96% decrease in NK cells
(CD49b+ with Dx5 mAb and CD335+ with NKp46 29A1.4 mAb) and < 10%
change in CD3+, CD4+, CD8+, and CD19+ cells, measured by flow cytometry
using Miltenyi MACSQuant flow cytometer. Control group received three
injections of normal rabbit IgG.
Whole-Genome Arrays and Quantitative Real-Time Reverse
Transcription PCR
Whole-genome arrays (Affymetrix Mouse GeneChip Gene 1.0 ST Array) were
used to measure gene expression in untreated and DSS-treated (5%, 48 hr)
WT and Pglyrp1/, Pglyrp2/, Pglyrp3/, and Pglyrp4/mice (5 per group,
50 mice total). RNA from each mouse (isolated as described in the Supple-
mental Information) was individually processed and hybridized. The cDNA
synthesis and labeling, hybridization, scanning, and data extraction were
done as described in the Supplemental Information. We first compared induc-
tion of gene expression in the colon after 2 days of 5% DSS treatment in
each knockout strain individually (Pglyrp1/, Pglyrp2/, Pglyrp3/, and
Pglyrp4/) to the induction of gene expression by DSS in WT mice. We
compared the fold induction of mRNA in the colon of Pglyrp/ mice treated
with DSS to untreated Pglyrp/mice, the fold induction of mRNA in the colon
of WT mice treated with DSS to untreated WT mice, the significance of differ-
ences between the fold induction of mRNA in Pglyrp/ versus WT mice, and
the ratio of the fold induction of mRNA in the colon of Pglyrp/ mice treated
with DSS to WT mice treated with DSS for each gene, which were calculated
as described in the Supplemental Information. For each data set comparing
Pglyrp/ mice to WT mice, we arranged all of the genes on the array in de-
scending order from the highest to the lowest ratio of gene induction in
Pglyrp/ mice versus WT mice. The entire array data sets, including these
calculations, have been deposited in NCBI GEO (accession number
GSE18859).
We then merged the above four whole-genome array data sets for
Pglyrp1/, Pglyrp2/, Pglyrp3/, and Pglyrp4/ mice (each compared to
WT mice) and identified the top common 75 genes differentially expressed in
all PGRP-deficient versus WT mice. Predicted genes, gene models, unidenti-
fied genes, and ESTs were omitted from this top 75 genes list. The results with
these top 75 genes are presented here in Figure 3A and Table S3.
Quantitative reverse transcription real-time PCR (qRT-PCR) was used to
quantify the amounts of mRNA in colon, colonic epithelial cells, or colonicst & Microbe 8, 147–162, August 19, 2010 ª2010 Elsevier Inc. 159
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PCRArray, or, for other genes, using customRT2 Profiler PCRArrays designed
by us, or individual primer sets (all from SA Biosciences), as described
previously (Saha et al., 2009) and in the Supplemental Information. The lists
of genes are provided in Tables S1 and S3–S5. The results were calculated
as described in the Supplemental Information and reported as mean fold
increases after DSS treatment (DSS treated/untreated) for each strain or ratios
of fold increases in PGRP-deficient to WT mice.
Cell Isolation, Culture, and Cytokine Production
Mouse primary colonic epithelial cells, colonic fibroblasts, and peritoneal
macrophages were isolated as described in the Supplemental Information.
Colonic fibroblasts or macrophages were then seeded into 10 cm plates for
RNA isolation or into 24-well plates for cytokine secretion. Details of cell
culture, stimulation, and qRT-PCR and ELISA assays for IL-6 and CXCL-1
are given in the Supplemental Information.
qPCR for Stool Flora Analysis
The abundance of specific bacterial groups in mouse stools was measured by
qPCR using group-specific 16 s rDNA primers (Barman et al., 2008; Salzman
et al., 2010) as described in the Supplemental Information.
Germ-Free Mice Experiments
Germ-free mice (Swiss Webster female, 4- to 5-week-old from Taconic
Farms), maintained under sterile conditions, were treated with 4% DSS in
drinking water and gavaged daily into the stomach with 12 mg stools from
WT, Pglyrp2/, or Pglyrp3/ mice prepared as described in the Supple-
mental Information. The development of colitis was evaluated as described
above.
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The entire whole-genome array data sets (including calculations) have been
deposited in the NCBI’s Gene Expression Omnibus (GEO) (Edgar et al.,
2002) and are accessible through GEO Series accession number GSE18859
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18859).
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